Quantcast

Latest ViiV Healthcare Stories

2014-06-12 08:28:17

Agreement is ViiV Healthcare's first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine LONDON, June 12, 2014 /PRNewswire/ -- ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland Ltd (Janssen) for the development and commercialisation of a single-tablet combining dolutegravir (Tivicay®) and Janssen's non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant®([1])). This...

2014-06-10 08:29:37

Key findings point to significant differences between treated and untreated people living with HIV RESEARCH TRIANGLE PARK, N.C., June 10, 2014 /PRNewswire/ -- ViiV Healthcare today announced new survey data that provide important insights that may help explain why HIV treatment rates remain low in the United States. Findings from the online survey, conducted by Harris Interactive on behalf of ViiV Healthcare in 2013, reveal gaps in knowledge about HIV and its treatment among diagnosed but...

2014-04-01 16:25:28

Elizabeth Glaser Pediatric AIDS Foundation Applauds Agreement between the Medicines Patent Pool and ViiV Healthcare WASHINGTON, April 1, 2014 /PRNewswire-USNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare to increase access to dolutegravir (DTG), a promising new antiretroviral (ARV) medication. This agreement will allow generic manufacturers to scale up production of...

2014-04-01 16:25:22

GENEVA, April 1, 2014 /PRNewswire/ -- Access to dolutegravir could improve millions of lives in developing countries The Medicines Patent Pool (MPP) and ViiV Healthcare announced a new collaboration on HIV medicines today, signing two licensing agreements to increase access to dolutegravir (DTG), a promising new antiretroviral, for both adult and paediatric care. The agreements would allow generic...

2014-04-01 16:25:15

- Timely collaborations underscore ViiV Healthcare's commitment to increase access to life-saving HIV medicines for children and adults in the developing world LONDON, April 1, 2014 /PRNewswire/ -- ViiV Healthcare today announced new collaborations with the goal of increasing access to its HIV medicine, dolutegravir (marketed under the name Tivicay®), just two months after its approval by the European Medicines Agency (EMA) and eight months after approval by the US Food and Drug...

2014-02-03 23:02:45

Insightful research report “HIV - KOL Insight and Consensus Outlook Modules” worked out by FirstWord has been recently published by Market Publishers Ltd. According to the study, the HIV therapies market is forecast to maintain stable growth in upcoming years. London, UK (PRWEB) February 03, 2014 During 2007-2012, the HIV therapies market registered a CAGR of 12%; however, keeping the growth pace at a high level will be a key challenge in the upcoming years. Currently, the HIV market...